Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Akorn AKRX is 18.99%. Akorn's revenue for the same period is $227.26 million. The trailing-twelve-month return on equity at Hi Tech Pharmacal Co HITK is 18.38%. Hi Tech Pharmacal's operating margin for the same period is 24.58%. The trailing-twelve-month return on equity at Salix Pharmaceuticals SLXP is 15.84%. Salix Pharmaceuticals had $775.90 million in total cash for the latest quarter. The trailing-twelve-month return on equity at Mylan MYL is 14.65%. Mylan's PEG ratio is 0.72.